Frontiers in Oncology (Dec 2020)
Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
- Andrés F. Cardona,
- Andrés F. Cardona,
- Alejandro Ruiz-Patiño,
- Alejandro Ruiz-Patiño,
- Oscar Arrieta,
- Luisa Ricaurte,
- Zyanya Lucia Zatarain-Barrón,
- July Rodriguez,
- July Rodriguez,
- Jenny Avila,
- Jenny Avila,
- Leonardo Rojas,
- Leonardo Rojas,
- Leonardo Rojas,
- Gonzalo Recondo,
- Feliciano Barron,
- Pilar Archila,
- Carolina Sotelo,
- Carolina Sotelo,
- Melissa Bravo,
- Nataly Zamudio,
- Luis Corrales,
- Claudio Martín,
- Christian Rolfo,
- Lucia Viola,
- Hernán Carranza,
- Hernán Carranza,
- Hernán Carranza,
- Carlos Vargas,
- Carlos Vargas,
- Carlos Vargas,
- Jorge Otero,
- Jorge Otero,
- Jorge Otero,
- Maritza Bermudez,
- Maritza Bermudez,
- Tatiana Gamez,
- Tatiana Gamez,
- Luis Eduardo Pino,
- Rafael Rosell
Affiliations
- Andrés F. Cardona
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Andrés F. Cardona
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Alejandro Ruiz-Patiño
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Alejandro Ruiz-Patiño
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Oscar Arrieta
- Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México
- Luisa Ricaurte
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Zyanya Lucia Zatarain-Barrón
- Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México
- July Rodriguez
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- July Rodriguez
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Jenny Avila
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Jenny Avila
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Leonardo Rojas
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Leonardo Rojas
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Leonardo Rojas
- Oncology Department, Clínica Colsanitas, Bogotá, Colombia
- Gonzalo Recondo
- Thoracic Oncology Section, Centro de Educación Médica e Investigaciones Clínicas – CEMIC, Buenos Aires, Argentina
- Feliciano Barron
- Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México
- Pilar Archila
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Carolina Sotelo
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Carolina Sotelo
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Melissa Bravo
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Nataly Zamudio
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Luis Corrales
- Oncology Department, Hospital San Juan de Dios, San José Costa Rica, Costa Rica
- Claudio Martín
- Medical Oncology Group, Fleming Institute, Buenos Aires, Argentina
- Christian Rolfo
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States
- Lucia Viola
- 0Thoracic Oncology Unit, Fundación Neumológica Colombiana, Bogotá, Colombia
- Hernán Carranza
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Hernán Carranza
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Hernán Carranza
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Carlos Vargas
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Carlos Vargas
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Carlos Vargas
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Jorge Otero
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- Jorge Otero
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Jorge Otero
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Maritza Bermudez
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Maritza Bermudez
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Tatiana Gamez
- Department of Medical Oncology, Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- Tatiana Gamez
- Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
- Luis Eduardo Pino
- 1Department of Medical Oncology, Fundación Santa Fé de Bogotá, Bogotá, Colombia
- Rafael Rosell
- 2Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain
- DOI
- https://doi.org/10.3389/fonc.2020.588932
- Journal volume & issue
-
Vol. 10
Abstract
BackgroundLung cancer is a public health problem, and squamous cell carcinoma (SCC) is the second most prevalent subtype of this neoplasm. Compared to other subtypes, including adenocarcinoma, SCC is less well understood in terms of molecular pathogenesis, limiting therapeutic options among targeted agents approved for other disease subgroups. In this study, we sought to characterize the SCC genomic profile using a validated Next Generation Sequencing (NGS) platform.MethodsThe comprehensive NGS assay (TruSight Tumor 170) was used in order to target the full coding regions of 170 cancer-related genes on SCC samples. PD-L1 expression in tumor cells (TCs) was assessed using clone 22C3 (Dako). Clinical outcomes were correlated with molecular profile, including progression free survival (PFS), overall response rate (ORR), and overall survival (OS).ResultsA total of 26 samples were included, median age was 67 years (r, 33–83) and 53.8% were men. Tobacco consumption was identified in all subjects (mean 34-year package). For first-line treatment 80.8% of patients received cisplatin or carboplatin plus gemcitabine. In terms of molecular profile, we identified a high prevalence of inactivating mutations in TP53 (61.5%), PIK3CA (34.6%), MLL2 (34.6%), KEAP1 (38.4%), and NOTCH1 (26.9%). PD-L1 expression ranged from negative, 1, 2–49, and ≥50% in 23.1, 38.5, 26.9, and 11.5%, respectively. Interestingly, the genetic alterations did not have an effect in PFS, OS or ORR in this study. However, PDL1 expression was higher among those who had mutations in TP53 (p = 0.037) and greater expression of PDL1 was related to PIK3CA alterations (p = 0.05).ConclusionsThe genomic profile of SCC encompasses important genes including TP53, PIK3CA and KEAP1. TP53 mutations could be associated with PDL1 expression, generating hypothesis regarding specific treatment options.
Keywords